efficacy and safety of peginterferon alpha-2a [pegasys] monotherapy in the treatment of chronic hepatitis C infected subjects with transfusion dependent thalassemia

ABSTRACT

Background and aims: interferon monotherapy is currently the only approved treatment for chronic hepatitis C [CHC] infection in transfusion dependent thalassemic patients, in whom ribavirin has limited use because of its hematologic complications. Our aim was to evaluate the efficacy and safety of pegylated Interferon monotherapy for the treatment of HCV infection in transfusion dependent thalassemic patients